JP7645801B2 - Ｃｄ３８に特異的な二環式ペプチドリガンド - Google Patents

Ｃｄ３８に特異的な二環式ペプチドリガンド Download PDF

Info

Publication number
JP7645801B2
JP7645801B2 JP2021540842A JP2021540842A JP7645801B2 JP 7645801 B2 JP7645801 B2 JP 7645801B2 JP 2021540842 A JP2021540842 A JP 2021540842A JP 2021540842 A JP2021540842 A JP 2021540842A JP 7645801 B2 JP7645801 B2 JP 7645801B2
Authority
JP
Japan
Prior art keywords
seq
referred
acid
peptide
peptide ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021540842A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517040A (ja
JPWO2020148529A5 (enExample
Inventor
バルダッサーレ レオナルド
ラニ ラシッド
パヴァン シルヴィア
ステイス キャサリン
トイフェル ダニエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Publication of JP2022517040A publication Critical patent/JP2022517040A/ja
Publication of JPWO2020148529A5 publication Critical patent/JPWO2020148529A5/ja
Priority to JP2024185776A priority Critical patent/JP2025023938A/ja
Application granted granted Critical
Publication of JP7645801B2 publication Critical patent/JP7645801B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021540842A 2019-01-15 2020-01-15 Ｃｄ３８に特異的な二環式ペプチドリガンド Active JP7645801B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024185776A JP2025023938A (ja) 2019-01-15 2024-10-22 Ｃｄ３８に特異的な二環式ペプチドリガンド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1900529.7 2019-01-15
GBGB1900529.7A GB201900529D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for CD38
PCT/GB2020/050073 WO2020148529A1 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for cd38

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024185776A Division JP2025023938A (ja) 2019-01-15 2024-10-22 Ｃｄ３８に特異的な二環式ペプチドリガンド

Publications (3)

Publication Number Publication Date
JP2022517040A JP2022517040A (ja) 2022-03-03
JPWO2020148529A5 JPWO2020148529A5 (enExample) 2023-01-25
JP7645801B2 true JP7645801B2 (ja) 2025-03-14

Family

ID=65528180

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021540842A Active JP7645801B2 (ja) 2019-01-15 2020-01-15 Ｃｄ３８に特異的な二環式ペプチドリガンド
JP2024185776A Pending JP2025023938A (ja) 2019-01-15 2024-10-22 Ｃｄ３８に特異的な二環式ペプチドリガンド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024185776A Pending JP2025023938A (ja) 2019-01-15 2024-10-22 Ｃｄ３８に特異的な二環式ペプチドリガンド

Country Status (6)

Country Link
US (1) US20220064218A1 (enExample)
EP (1) EP3911365A1 (enExample)
JP (2) JP7645801B2 (enExample)
CN (1) CN113543813B (enExample)
GB (1) GB201900529D0 (enExample)
WO (1) WO2020148529A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3215518T1 (sl) 2014-10-29 2021-08-31 Bicyclerd Limited Biciklični peptidni ligandi, značilni za MT1-MMP
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
WO2019162682A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016067035A1 (en) 2014-10-29 2016-05-06 Bicycle Therapeutics Limited Bicyclic peptide ligands specific for mt1-mmp
JP2016527180A (ja) 2013-03-15 2016-09-08 バイサイクル・セラピューティクス・リミテッド ポリペプチドの修飾
US20180118786A1 (en) 2015-04-28 2018-05-03 Ecole Polytechnique Federale De Lausanne (Epfl) NOVEL lNHIBITORS OF THE ENZYME ACTIVATED FACTOR XII (FXIIA)
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
ES2509959T5 (en) * 2008-02-05 2024-12-19 Bicyclerd Ltd Methods and compositions
GB201600903D0 (en) * 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Peptide derivaties
GB201600911D0 (en) * 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives
GB201810320D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016527180A (ja) 2013-03-15 2016-09-08 バイサイクル・セラピューティクス・リミテッド ポリペプチドの修飾
WO2016067035A1 (en) 2014-10-29 2016-05-06 Bicycle Therapeutics Limited Bicyclic peptide ligands specific for mt1-mmp
US20180118786A1 (en) 2015-04-28 2018-05-03 Ecole Polytechnique Federale De Lausanne (Epfl) NOVEL lNHIBITORS OF THE ENZYME ACTIVATED FACTOR XII (FXIIA)
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Liuhong Chen, et al.，The Bicycle platform: an efficient technology to generate high affinity, high selectivity molecules，Bicycle therapeutics Publications [online]，2017年，https://www.bicycletherapeutics.com/wp-content/uploads/16_PEGS-Bicycle_-30-04-2017-poster.pdf，[2023年12月25日検索]

Also Published As

Publication number Publication date
JP2022517040A (ja) 2022-03-03
CN113543813A (zh) 2021-10-22
JP2025023938A (ja) 2025-02-19
GB201900529D0 (en) 2019-03-06
US20220064218A1 (en) 2022-03-03
CN113543813B (zh) 2024-03-29
EP3911365A1 (en) 2021-11-24
WO2020148529A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
JP7645801B2 (ja) Ｃｄ３８に特異的な二環式ペプチドリガンド
JP7579840B2 (ja) ヘテロタンデム二環式ペプチド複合体
US12377155B2 (en) Bicyclic peptide ligands specific for PSMA
EP3452096B1 (en) Bicyclic peptide-toxin conjugates specific for mt1-mmp
JP2025020121A (ja) Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
JP7658902B2 (ja) Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
CA3154672A1 (en) Bicyclic peptide ligand drug conjugates
US20220133733A1 (en) Bicyclic peptide ligands specific for cd38
US20210122804A1 (en) Peptide ligands for binding to cd38
EP3911665A1 (en) Bicyclic peptide ligands specific for caix
EP3894005A1 (en) Bicyclic peptide ligands specific for fap-alpha
EP4077349A1 (en) Bicyclic peptide ligands specific for il-17
WO2022079445A1 (en) Bicyclic peptide ligand drug conjugates
JP2023506874A (ja) Ｉｌ－１７に特異的な二環式ペプチドリガンド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241022

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250304

R150 Certificate of patent or registration of utility model

Ref document number: 7645801

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150